Currently, there are 1.33M common shares owned by the public and among those 1.03M shares have been available to trade.
Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 171,756 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
However, the script later moved the day high at 1.8800, up 53.44%. The company’s stock has a 5-day price change of 61.97% and -69.66% over the past three months. BFRI shares are trading -58.48% year to date (YTD), with the 12-month market performance down to -92.98% lower. It has a 12-month low price of $0.61 and touched a high of $16.40 over the same period. BFRI has an average intraday trading volume of 245.46K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.89%, -46.07%, and -82.97% respectively.
Institutional ownership of Biofrontera Inc (NASDAQ: BFRI) shares accounts for 16.86% of the company’s 1.33M shares outstanding.
It has a market capitalization of $1.58M and a beta (3y monthly) value of 0.59. The earnings-per-share (ttm) stands at -$19.56. Price movements for the stock have been influenced by the stock’s volatility, which stands at 27.85% over the week and 18.14% over the month.
Analysts forecast that Biofrontera Inc (BFRI) will achieve an EPS of -$0.98 for the current quarter, -$0.77 for the next quarter and -$3.07 for 2024. The lowest estimate earnings-per-share for the quarter is -$1.11 while analysts give the company a high EPS estimate of -$0.85. Comparatively, EPS for the current quarter was -$2.8 a year ago. Earnings per share for the fiscal year are expected to decrease by -2671.67%, and 81.54% over the next financial year.
